Trumprx.gov launched with much fanfare late Feb. 5, and the online tool brings promise for the “world’s lowest prices” on prescription drugs. Alongside the website hoopla came word from Hims & Hers Health of its own steep discounts on what’s to be the compounded version of a Trumprx-featured therapy: oral Wegovy (semaglutide) for obesity. Novo Nordisk A/S, Wegovy’s originator, vowed to fight. Read More
On the heels of an NDA submission for brepocitinib in dermatomyositis, Priovant Therapeutics Inc. disclosed data showing the dual TYK2/JAK1 inhibitor surpassed expectations in a phase II study in cutaneous sarcoidosis, another chronic inflammatory skin condition with limited treatment options, setting the stage for a phase III study set to start this year. Read More
Bayer AG’s oral factor XIa inhibitor asundexian significantly reduced ischemic stroke by 26% in patients following a noncardioembolic ischemic stroke or high-risk transient ischemic attack in the phase III Oceanic-Stroke study. Read More
Total biopharma financings rose to $10.79 billion in January 2026, up from $9.08 billion in December. The monthly total nearly matched the January 2024 record of $10.9 billion, far exceeding the $6.82 billion average monthly haul in 2025. Read More
Paragonix Technologies Inc.’s Kidneyvault portable renal perfusion system managed to preserve and enable the reallocation of a donor kidney for more than 29 hours, despite prolonged ischemic time, multiple handoffs and two commercial flights. Throughout the period, the Kidneyvault maintained stable hypothermic preservation, preventing the organ from being discarded and allowing it to be transplanted into a patient. Read More
A jury in a U.S. District Court unanimously found that Medtronic plc violated federal and state antitrust laws relating to its blood sealing surgical devices and must pay $382 million in damages to Applied Medical Resources Corp. Read More
After keeping the faith when it failed in the Modify phase III trial in October 2021, Idorsia Ltd. now has a clear route to market for lucerastat, an oral therapy for Fabry disease. Read More
Insight Lifetech Co. Ltd. listed on the Shanghai Stock Exchange’s STAR market via an unprofitable biotech track reinstated last year, with the Feb. 5 IPO raising ¥998.64 million (US$143.93 million). Read More
Another two biopharma companies priced IPOs on Nasdaq to raise a combined $350 million, becoming the fourth and fifth firms to debut on U.S. markets in 2026. Read More
Scientists at Ghent University have created a mouse model that incorporates human versions of the receptors that recognize the fragment crystallizable region of immunoglobulin G, one of the most abundant antibodies in the blood and a key mediator of essential immune functions such as cellular activation, pathogen elimination and the regulation of inflammatory responses. Read More
Beginning Feb. 2, 2026, medical technology news and analysis will be integrated into BioWorld, where curated coverage will continue as part of BioWorld’s core reporting. Read More
New hires and promotions in the biopharma and med-tech industries, including: Adarx, Angitia, Braveheart, Calico, Iveena, Polaryx, Primmune, Renovorx, Tempest, Vectory. Read More
Biopharma and med-tech companies raising money in public or private financings, including: Angitia, Collplant, GE Medical Holding, Generate, Exact, Inspira, LB, Myndtec. Read More
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Apotex, Chemometec, Eisai, Grünenthal, Henlius, Endomimetics, Everest, Factor, Imunon, Liger, Micot, Phase Scientific, Roche, Searchlight, Tempest, Watchmaker, Visby, Vectus, Xortx. Read More
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Biocomposites, Eyas, Insightec, Mirum, Sonorous Neurovascular. Read More
